News & Trends

• 272026-03

  Salubris Obtains Exclusive License for Pruritus Drug STC007 Collaboration Announcement

• 252026-03

  Salubris’ Investigational Drug SAL0145 Approved for Clinical Trial for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

• 242026-03

  Salubris’ Self-Developed Investigational Drug SAL0150 Approved for Clinical Trial for the Treatment of Type 2 Diabetes and Obesity

• 212025-10

  Breakthrough in Clinical Trials of Innovative Anti-Cancer Drug JK06 Shows Potential in Treating Advanced Solid Tumors

• 152025-10

  Breaking News: Salubris' SAL0137 Clinical Trial Application Accepted for Treatment of Elevated Lipoprotein(a)

• 302025-09

  Breaking News: Salubris Achieves Phase Progress in Two Independently Innovated Biologic Drugs